Benefits of pre-surgical immunotherapy were independent of race in patients with aggressive breast cancer

Treatment outcomes were similar between Black and non-Black patients with triple-negative breast cancer who received neoadjuvant durvalumab (Imfinzi) plus chemotherapy, according to phase I/II clinical trial results published in Clinical Cancer Research.

source https://medicalxpress.com/news/2022-07-benefits-pre-surgical-immunotherapy-independent-patients.html